|
Market Closed -
NYSE
23:03:09 14/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 111.25 USD | -0.02% |
|
+3.19% | -11.21% |
| 08-13 | Citigroup Adjusts Price Target on Abbott Laboratories to $125 From $112, Maintains Buy Rating | MT |
| 08-13 | Wolfe Research Upgrades Abbott Laboratories to Outperform From Peer Perform, PT is $130 | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 192,505 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -11.64% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 216,444 | 213,462 | 209,772 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -2.62% | -1.38% | -1.73% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 31.9x | 24.6x | 21.9x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 4.02x | 3.85x | 3.65x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.07x | 0.8x | 1.8x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.83x | 3.52x | 3.3x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.3x | 3.91x | 3.59x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16.7x | 14.7x | 13.2x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 18.5x | 16.4x | 14.7x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 27.3x | 22.8x | 20.5x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.66% | 4.38% | 4.87% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.31% | 2.46% | 2.6% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.486 | 4.524 | 5.074 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.6% | 57.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,303 | 54,647 | 58,411 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,999 | 14,497 | 15,883 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,314 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,232 | 7,924 | 8,850 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 111.25 | 111.25 | 111.25 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 1/26/22 A | 1/25/23 A | 1/24/24 A | 1/22/25 A | 1/22/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.91x | 4.3x | 16.65x | 2.31% | 193B | |
| 20.68x | 3.58x | 12.58x | 3.26% | 117B | |
| 17.18x | 0.2x | 12.43x | 0.76% | 59.89B | |
| 32.51x | 8.12x | 20.71x | 1.22% | 56.01B | |
| 35.34x | 3.41x | 11.7x | 2.14% | 49.96B | |
| 35.98x | 6.33x | 19.87x | -.--% | 33.87B | |
| 46.51x | 1.32x | 12.08x | 0.16% | 31.36B | |
| 20.88x | 3.19x | 11.7x | 1.4% | 24.77B | |
| 40.75x | 7.14x | 25.62x | 0.26% | 24.59B | |
| 25.12x | 3.78x | 13.18x | 1.14% | 22.74B | |
| Average | 30.69x | 4.14x | 15.65x | 1.26% | 61.25B | |
| Weighted average by Cap. | 29.29x | 4.05x | 15.40x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
